Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 1391 to 1400 of 2586 total matches.

Comparison Table: Triptans for Migraine (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023  (Issue 1678)
▶ Comparison Table: Triptans Last updated: June 12, 2023 Comparison Table: Triptans Drug ...
View the Comparison Table: Triptans for Migraine
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e97-9   doi:10.58347/tml.2023.1678b |  Show IntroductionHide Introduction

Bimekizumab (Bimzelx) for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024  (Issue 1694)
expensive than other oral drugs, but it increases the risk of infection and can cause serious hematologic ...
The FDA has approved the injectable interleukin (IL)-17A/17F antagonist bimekizumab-bkzx (Bimzelx – UCB) for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic treatment or phototherapy. Bimekizumab is the first IL-17A/17F antagonist to be approved in the US. It was approved in the European Union for the same indication in 2021.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):11-3   doi:10.58347/tml.2024.1694b |  Show IntroductionHide Introduction

Tretinoin for Aging Skin

   
The Medical Letter on Drugs and Therapeutics • Jul 15, 1988  (Issue 770)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Tretinoin (all-trans-retinoic acid; Retin-A), a vitamin A metabolite used for years for topical treatment of acne, is now being used (without the approval of the US Food and Drug Administration) to improve the appearance of aging skin. Available by prescription in various concentrations in cream, gel and liquid formulations, tretinoin is chemically similar to isotretinoin (13-cis-retinoic acid; Accutane), an oral drug used for treatment of severe acne which has recently caused concern because of its teratogenicity (Morbid Mortal Weekly Rep, 37:171, March 25, 1988).
Med Lett Drugs Ther. 1988 Jul 15;30(770):69-70 |  Show IntroductionHide Introduction

Dezocine

   
The Medical Letter on Drugs and Therapeutics • Oct 19, 1990  (Issue 829)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Dezocine (Dalgan - Astra), a new synthetic opioid agonist/antagonist structurally related to pentazocine (Talwin), was recently approved for parenteral use as an analgesic by the US Food and Drug Administration.
Med Lett Drugs Ther. 1990 Oct 19;32(829):95-6 |  Show IntroductionHide Introduction

Bicalutamide for Prostate Cancer

   
The Medical Letter on Drugs and Therapeutics • Jun 21, 1996  (Issue 977)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Bicalutamide (Casodex - Zeneca), an oral nonsteroidal antiandrogen similar to flutamide (Eulexin - Medical Letter, 31:72, 1989), is now available in the USA for treat-ment of advanced prostate cancer. The drug is recommended by the manufacturer for use concurrently with an analog of luteinizing hormone-releasing hormone (LHRH) such as leuprolide (Lupron; Lupron Depot) or goserelin (Zoladex -Medical Letter, 32:102, 1990).
Med Lett Drugs Ther. 1996 Jun 21;38(977):56-7 |  Show IntroductionHide Introduction

In Brief: Sodium Phosphate Colonoscopy Preps

   
The Medical Letter on Drugs and Therapeutics • May 22, 2006  (Issue 1235)
Letter ® On Drugs and Therapeutics Volume 48 (Issue 1235) May 22, 2006 www.medicalletter.org ...
Last year, a Medical Letter article reviewing colonoscopy preparations warned that oral sodium phosphate preparations, such as Fleet Phospho-Soda solution and Visicol tablets, could cause significant electrolyte disturbances and, rarely, renal failure (Med Lett Drugs Ther 2005; 47:53). A subsequent report documented acute phosphate nephropathy and renal failure in 21 patients who had used sodium phosphate before colonoscopy (GS Markowitz et al. J Am Soc Nephrol 2005; 16:3389). Seventeen of these patients were women and 14 were taking an angiotensin-converting enzyme (ACE) inhibitor or...
Med Lett Drugs Ther. 2006 May 22;48(1235):41 |  Show IntroductionHide Introduction

In Brief: Influenza Developments

   
The Medical Letter on Drugs and Therapeutics • Mar 24, 2008  (Issue 1282)
Letter ® On Drugs and Therapeutics Volume 50 (Issue 1282) March 24, 2008 www.medicalletter.org ...
Recent reports (D Kaye.Clin Infect Dis April 1, 2008;46:iii) indicate that 2 of the 3 components of this year's influenza vaccine (Med Lett Drugs Ther 2007;49:81), the influenza B and A/H3N2 antigens, do not matchup well with circulating strains. The B component is probably not protective. The A/H3N2 antigen in the vaccine probably provides some protection, particularly for high-risk patients. The third component, the A/H1N1 antigen, is protective against circulating A/H1N1 influenza viruses, but these viruses, unlike previous A/H1N1 strains, are developing some resistance to oseltamivir...
Med Lett Drugs Ther. 2008 Mar 24;50(1282):21-4 |  Show IntroductionHide Introduction

In Brief: Meningococcal Prophylaxis

   
The Medical Letter on Drugs and Therapeutics • Apr 07, 2008  (Issue 1283)
Letter ® On Drugs and Therapeutics Volume 50 (Issue 1283) April 7, 2008 www.medicalletter.org ...
The CDC recently reported that fluoroquinoloneresistant strains of Neisseria meningitidis have been detected for the first time in the US in an area around the border of North Dakota and Minnesota (CDC. MMWR, Feb 22, 2008). These isolates were all serogroup B, for which meningococcal vaccines (Med Lett Drugs Ther 2005; 47:29) do not offer protection. Since many laboratories do not test N. meningitidis for antimicrobial susceptibility, it is possible that such resistance is more widespread. A single oral dose of ciprofloxacin (Cipro, and others) 500 mg has been used for prophylaxis after close...
Med Lett Drugs Ther. 2008 Apr 7;50(1283):25 |  Show IntroductionHide Introduction

Correction: Bendamustine (Treanda) for CLL and NHL

   
The Medical Letter on Drugs and Therapeutics • Dec 01, 2008  (Issue 1300)
Letter ® On Drugs and Therapeutics Volume 50 (Issue 1300) December 1, 2008 www.medicalletter.org ...
(Med Lett Drugs Ther 2008; 50:91) In the Clinical Studies section, the complete response rate with chlorambucil for CLL was 2% (not 24%).
Med Lett Drugs Ther. 2008 Dec 1;50(1300):96 |  Show IntroductionHide Introduction

Correction: A Sumatriptan Needle-Free Injection for Migraine

   
The Medical Letter on Drugs and Therapeutics • Jul 12, 2010  (Issue 1342)
The Medical Letter ® On Drugs and Therapeutics Published by The Medical Letter, Inc. • 1000 ...
In The Medical Letter article on Sumatriptan Needle-Free Injection for Migraine (2010; 52:50), on page 51, in Table 2, the injection volumes of Imitrex and Sumaval are listed as 5 mL. They should be 0.5 mL.
Med Lett Drugs Ther. 2010 Jul 12;52(1342):56 |  Show IntroductionHide Introduction